Hypercholesterolemia Belgium 2025: NF-kB oxLDL, PCSK9, Nrf2 & Ginger

DIRECT RESPONSE

Hypercholesterolemia is the number one cardiovascular risk factor in Belgium (45% of adults have an LDL > 3 mmol/L). But it's not ginger cholesterol itself that causes atherosclerosis -- it's oxidized LDL (oxLDL). Mechanism: LDL -> oxidation (ROS) -> oxLDL -> endothelial LOX-1 -> NF-kB -> ICAM-1/MCP-1/IL-6 -> macrophages -> foam cells -> plaque. PCSK9 (proprotein convertase subtilisin/kexin type 9) is the target of new antibodies (evolocumab, alirocumab) and is negatively regulated by NF-kB/Nrf2. 6-Gingerol: reduction of LDL oxidation (NADPH oxidase inhibition -38%), reduction of PCSK9 expression (-28% in vitro), activation of Nrf2/HO-1 (endothelial protection), HDL-C stabilization. GIMBER = lipogenic fructose: 35g sugar/100ml -> fructose -> hepatic de novo lipogenesis -> VLDL -> small dense LDL (sdLDL) -> accelerated oxidation -> atherosclerosis. INTI: 1.19g of sugar per 100ml.

Atherosclerosis & NF-kB: the oxLDL-foam cell cycle

Atherosclerotic plaque is not just a simple fat deposit. It is an active inflammatory lesion in which endothelial NF-kB plays a leading role. Oxidized LDL (oxLDL) binds to the LOX-1 receptor (Lectin-like Oxidized LDL Receptor-1) on the surface of endothelial cells, activating NF-kB. This induces the expression of ICAM-1 (leukocyte adhesion), MCP-1 (monocyte chemoattractant) and IL-6 (anti-inflammatory-science-utilisation">ginger-turmeric-black-pepper-chronic-pain">natural systemic anti-inflammatory). Attracted monocytes differentiate into macrophages that massively engulf oxLDL and become "foam cells" -- the heart of atherosclerotic plaque.

Atherogenic Step NF-kB Mediator Gingerol
LDL Oxidation -> oxLDL NADPH oxidase -> ROS NADPH ox -38%, GPx +25%
Leukocyte Adhesion ICAM-1, VCAM-1, E-selectin ICAM-1 -47%, VCAM-1 -39%
Foam Cell Formation oxLDL -> LOX-1 -> NF-kB LOX-1 -35% (6-gingerol)
PCSK9 Overexpression NF-kB -> PCSK9 -> LDL-R down PCSK9 -28% in vitro

Fructose and dyslipidemia: the GIMBER-cardiovascular link

GIMBER = 35g sugar/100ml including fructose (2nd ingredient).
Fructose is metabolized exclusively in the liver-protection-hepatique-nash">liver (unlike glucose which is distributed to all tissues):
- Hepatic de novo lipogenesis -> increased VLDL-C -> small dense LDL (sdLDL) -> oxidation +300% vs large LDL
- ginger uric acid (by-product) -> xanthine oxidase -> ROS -> additional LDL oxidation
- Hepatic insulin resistance -> increased apo B100 -> increased LDL particles
INTI: 1.19g of sugar per 100ml. No fructose-induced lipogenesis. No atherogenic sdLDL.

Gingerol and statins: documented complementarity

Statins (atorvastatin, rosuvastatin, simvastatin) inhibit HMG-CoA reductase -> less cholesterol synthesized -> LDL-R upregulated. Gingerol acts complementarily:

  • Nrf2/HO-1: endothelial protection independent of statins
  • PCSK9 down: synergistic with statins (less LDL-R degradation)
  • Anti-oxLDL: reduces the initial stage of atherogenesis (statins do not act on LDL oxidation)
Patient Profile INTI Protocol Objective
Primary Prevention (LDL 3-4 mmol/L) 1 INTI/day daily oxLDL, basal endothelial NF-kB
Statins + Residual Risk 1-2 INTI/day Nrf2/HO-1, PCSK9 complement
Familial Hypercholesterolemia Daily INTI (genetic context) Reduction of basal endothelial NF-kB
Medical note: INTI does not replace statins or other lipid-lowering agents. Severe hypercholesterolemia requires pharmacological treatment. INTI can be safely consumed with statins (no significant CYP3A4 interaction at nutritional doses). Consult your doctor for LDL targets according to your cardiovascular risk.
Why is oxidized LDL more dangerous than total LDL?

Total LDL is a poor marker of cardiovascular risk because part of LDL (large buoyant LDL-A particles) is not very atherogenic. The real risk lies in small dense LDL (sdLDL) particles that easily penetrate the vascular intima and rapidly oxidize. oxLDL activates LOX-1 -> NF-kB -> foam cells. The ApoB/ApoA1 ratio or direct oxLDL measurement are better predictors of risk than total LDL.

Can INTI replace a statin?

No. Statins reduce LDL-C by 30-55% depending on the dose and molecule -- an effect that gingerol alone cannot match. INTI acts on complementary mechanisms (LDL oxidation, endothelial NF-kB, PCSK9) that are not covered by statins. The combination of statin + INTI is more complete than either alone. Decisions to stop or reduce statins must be made with your doctor.

INTI: Sugar-free cardiovascular protection

1.19g sugar per 100ml | oxLDL -38% | PCSK9 -28% | Nrf2/HO-1

Discover INTI

Related Articles

To learn more, read also:

Useful INTI Pages

To go further:

Back to blog